Hims & Hers Health, Inc.
Business
Hims & Hers Health, Inc. is a consumer-first digital health platform launched in 2017 that connects patients to licensed healthcare providers for telehealth consultations and prescription fulfillment. The company offers treatments for chronic conditions including sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, as well as laboratory testing and non-prescription wellness products. Operations span the United States, Canada, the United Kingdom, and parts of the European Union, with customers accessing services through mobile applications and websites on a subscription or one-time purchase basis.
Summary from 10-K filed 2026-02-23
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 2,348 | 1,477 | 872 | 527 | 272 | |
| Cost of revenue | 614 | 303 | 157 | 118 | 67 | |
| Gross profit | 1,733 | 1,173 | 715 | 409 | 204 | |
| Marketing | 919 | 679 | 446 | 273 | 136 | |
| Operations and support | 286 | 186 | 120 | 77 | 48 | |
| Technology and development | 149 | 79 | 48 | 29 | 22 | |
| General and administrative | 273 | 168 | 130 | 98 | 114 | |
| Total operating expenses | 1,628 | 1,111 | 744 | 477 | 320 | |
| Income (loss) from operations | 106 | 62 | −29 | −69 | −115 | |
| Change in fair value of equity securities | 4 | 0 | 0 | — | — | |
| Change in fair value of liabilities | −9 | 0 | −1 | — | — | |
| Other income, net | 23 | 10 | 9 | 3 | 445,000 | |
| Total other income, net | 18 | 10 | 8 | 3 | 4 | |
| Income (loss) before income taxes | 124 | 72 | −22 | −66 | −111 | |
| Benefit from (provision for) income taxes | 4 | 54 | −2 | 31,000 | 3 | |
| Net income (loss) | 128 | 126 | −24 | −66 | −108 | |
| Other comprehensive income (loss) | 3 | −200,000 | 153,000 | −140,000 | −126,000 | |
| Total comprehensive income (loss) | 131 | 126 | −23 | −66 | −108 | |
| Basic (in USD per share) | 0.57 | 0.58 | −0.11 | −0.32 | −0.58 | |
| Diluted (in USD per share) | 0.51 | 0.53 | −0.11 | −0.32 | −0.58 | |
| Basic (in shares) | 225 | 216 | 209 | 205 | 187 | |
| Diluted (in shares) | 258 | 237 | 209 | 205 | 187 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 229 | 221 | 97 | 47 | 72 | |
| Short-term available-for-sale investments | 349 | 80 | 124 | 133 | 175 | |
| Inventory | 80 | 64 | 22 | 22 | 14 | |
| Prepaid expenses and other current assets | 110 | 31 | 22 | 15 | 9 | |
| Total current assets | 768 | 396 | 265 | 217 | 270 | |
| Restricted cash | 0 | 856,000 | 856,000 | 856,000 | 856,000 | |
| Long-term available-for-sale investments | 351 | 0 | — | — | — | |
| Goodwill | 278 | 113 | 111 | 111 | 111 | |
| Property, equipment, and software, net | 312 | 82 | 36 | 11 | — | |
| Intangible assets, net | 196 | 43 | 19 | 22 | 26 | |
| Operating lease right-of-use assets | 137 | 11 | 10 | 5 | 5 | |
| Deferred tax assets, net | 83 | 62 | 0 | — | — | |
| Other long-term assets | 30 | 147,000 | 91,000 | 33,000 | 8 | |
| Total assets | 2,155 | 708 | 441 | 366 | 421 | |
| Accounts payable | 143 | 91 | 43 | 32 | 20 | |
| Accrued liabilities | 79 | 53 | 29 | 12 | 12 | |
| Deferred revenue | 127 | 75 | 8 | 1 | 3 | |
| Earn-out payable | 47 | 0 | — | — | — | |
| Earn-out liabilities | 4 | 0 | 7 | 0 | 43 | |
| Operating lease liabilities | 5 | 2 | 1 | 2 | 1 | |
| Total current liabilities | 404 | 221 | 88 | 48 | 79 | |
| Convertible senior notes, net | 973 | 0 | — | — | — | |
| Operating lease liabilities | 143 | 9 | 9 | 4 | 4 | |
| Earn-out liabilities | 53 | 0 | — | — | — | |
| Deferred tax liabilities, net | 29 | 0 | — | — | — | |
| Other long-term liabilities | 12 | 0 | 22,000 | 35,000 | 629,000 | |
| Total liabilities | 1,614 | 231 | 97 | 55 | 86 | |
| Commitments and contingencies (Note $14) | — | — | — | — | — | |
| Common stock Class A shares, par value $0.0001, 2,750,000,000 shares authorized and 218,867,898 and 212,459,586 shares issued and outstanding as of December 31, 2025 and 2024, respectively; Class V shares, par value $0.0001, 10,000,000 shares authorized and 8,377,623 shares issued and outstanding as of December 31, 2025 and 2024 | 23,000 | 22,000 | 21,000 | 21,000 | 20,000 | |
| Additional paid-in capital | 652 | 719 | 712 | 657 | 614 | |
| Accumulated other comprehensive income (loss) | 2 | −324,000 | −124,000 | −277,000 | −137,000 | |
| Accumulated deficit | −114 | −242 | −368 | −345 | −279 | |
| Total stockholders' equity attributable to the Company | 541 | 477 | 344 | 312 | 335 | |
| Total liabilities and stockholders' equity | 2,155 | 708 | 441 | 366 | 421 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 55 | 17 | 10 | 7 | 4 | |
| Stock-based compensation | 135 | 92 | 66 | 43 | 67 | |
| Change in fair value of liabilities | 9 | 0 | 1 | — | — | |
| Net accretion on securities | −2 | −4 | −6 | 146,000 | 2 | |
| Benefit from deferred taxes | −13 | −62 | −13,000 | −594,000 | −3 | |
| Impairment of long-lived assets | 531,000 | 114,000 | 429,000 | 1 | 0 | |
| Amortization of debt discount and issuance costs | 5 | 0 | 0 | — | — | |
| Non-cash operating lease cost | 12 | 3 | 2 | 2 | 2 | |
| Non-cash acquisition-related costs | 6 | 0 | 3 | 837,000 | 1 | |
| Non-cash other | −2 | 357,000 | 195,000 | 0 | 540,000 | |
| Inventory | −14 | −42 | −902,000 | −8 | −10 | |
| Prepaid expenses and other current assets | −52 | −9 | −6 | −6 | 3 | |
| Other long-term assets | −518,000 | −56,000 | −58,000 | 17,000 | −58,000 | |
| Accounts payable | 30 | 44 | 7 | 13 | 10 | |
| Accrued liabilities | −43 | 24 | 17 | 909,000 | 197,000 | |
| Deferred revenue | 52 | 68 | 6 | −2 | 1 | |
| Operating lease liabilities | −2 | −2 | −2 | −2 | −2 | |
| Earn-out payable | 0 | −3 | 0 | −10 | 0 | |
| Net cash provided by operating activities | 300 | 251 | 73 | −27 | −34 | |
| Purchases of available-for-sale investments | −726 | −161 | −157 | −188 | −267 | |
| Maturities of available-for-sale investments | 109 | 209 | 170 | 194 | 158 | |
| Proceeds from sales of available-for-sale investments | 0 | 725,000 | 2 | 36 | 3 | |
| Investment in website development and internal-use software | −17 | −11 | −9 | −5 | −4 | |
| Purchases of property, equipment, and intangible assets | −226 | −42 | −17 | −3 | −832,000 | |
| Acquisition of businesses, net of cash acquired | −145 | −15 | 0 | 0 | −46 | |
| Purchase of equity securities | −20 | 0 | 0 | — | — | |
| Net cash used in investing activities | −1,025 | −19 | −12 | 35 | −156 | |
| Proceeds from issuance of convertible senior notes, net of debt discount | 970 | 0 | 0 | — | — | |
| Purchases of capped calls related to convertible senior notes | −48 | 0 | 0 | — | — | |
| Proceeds from exercise of vested stock options | 11 | 27 | 2 | — | — | |
| Payments for taxes related to net share settlement of equity awards | −117 | −53 | −14 | −4 | −6 | |
| Repurchases of common stock | −90 | −83 | −2 | 0 | 0 | |
| Proceeds from employee stock purchase plan | 6 | 4 | 2 | 1 | 0 | |
| Payments for debt issuance costs | −3 | 0 | 0 | — | 0 | |
| Payments for acquisition-related earn-out consideration | 0 | −3 | 0 | −33 | 0 | |
| Proceeds from exercise of Class A common stock warrants | 0 | 333,000 | 0 | 0 | 787,000 | |
| Net cash provided by (used in) financing activities | 730 | −108 | −11 | −33 | 235 | |
| Foreign currency effect on cash and cash equivalents | 3 | −270,000 | −11,000 | −53,000 | −73,000 | |
| Increase in cash, cash equivalents, and restricted cash | 7 | 124 | 50 | −25 | 44 | |
| Cash paid for taxes | 23 | 8 | 1 | 636,000 | 338,000 | |
| Purchases of property and equipment included in accounts payable and accrued liabilities | 25 | 8 | 3 | 0 | 0 | |
| Right-of-use asset obtained in exchange for lease liability | 133 | 3 | 6 | 1 | 0 | |
| Issuance of common stock in connection with asset acquisition | 13 | 0 | 0 | — | — | |
| Common stock to be issued for asset acquisition indemnification holdback | 6 | 0 | 0 | — | — | |
| Common stock issued, contingent consideration, additional consideration payable, and liabilities assumed in connection with acquisition of businesses | 200 | 16 | 0 | — | — | |
| Issuance of common stock for acquisition-related earn-out consideration | 0 | 1 | 0 | 0 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Hims & Hers Health, Inc.'s CIK number?
Hims & Hers Health, Inc.'s SEC CIK number is 0001773751 (1773751). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Hims & Hers Health, Inc.'s SEC filings?
All of Hims & Hers Health, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Hims & Hers Health, Inc. last report earnings?
Hims & Hers Health, Inc. (HIMS) most recently filed an earnings 8-K with the SEC on May 11, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001773751-26-000074). This is Hims & Hers Health, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Hims & Hers Health, Inc.'s most recent earnings 8-K?
Hims & Hers Health, Inc.'s latest earnings 8-K (Item 2.02) was filed May 11, 2026 under accession 0001773751-26-000074. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Hims & Hers Health, Inc.'s latest earnings 8-K →
Look up any company's CIK number →